Novasep has sold its U.S. subsidiary, TangenX Technology Corp., to Repligen Corp. for $39.0 million in cash.

In 2006, Novasep acquired a majority stake in TangenX, located in Shrewsbury, MA. The company develops, produces and sells tangential flow filtration (TFF) technologies designed to help biomanufacturers reduce industrial purification costs of biopharmaceuticals. Its single-use TFF cassettes Sius currently has strong sales.

“We are pleased to have finalized this deal with Repligen,” said Novasep chairman and chief executive officer, Dr. Michel Spagnol. “We were the first industrial investor in TangenX and supported the development and the launch of its innovative TFF technology. Repligen’s infrastructure, which is perfectly adapted to the Sius range, will help to develop the product at the pace this technology deserves.”

“For more than three years, Novasep has been pursuing its strategy aimed at refocusing the company on its core activities. This transaction reinforces our capacity to accelerate strategic growth,” he added.